206 related articles for article (PubMed ID: 27435393)
61. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
62. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
63. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
[TBL] [Abstract][Full Text] [Related]
64. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
65. Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer.
Tanaka N; Miyajima A; Kosaka T; Shirotake S; Hasegawa M; Kikuchi E; Oya M
Mol Cancer Ther; 2010 Nov; 9(11):2982-92. PubMed ID: 20978160
[TBL] [Abstract][Full Text] [Related]
66. WNT7B represses epithelial-mesenchymal transition and stem-like properties in bladder urothelial carcinoma.
Na L; Wang Z; Bai Y; Sun Y; Dong D; Wang W; Zhao C
Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166271. PubMed ID: 34562599
[TBL] [Abstract][Full Text] [Related]
67. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
[TBL] [Abstract][Full Text] [Related]
68. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
69. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
[TBL] [Abstract][Full Text] [Related]
70. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations.
Yan XD; Li M; Yuan Y; Mao N; Pan LY
Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060
[TBL] [Abstract][Full Text] [Related]
71. ROCK2 promotes HCC proliferation by CEBPD inhibition through phospho-GSK3β/β-catenin signaling.
Li M; Zhou W; Yuan R; Chen L; Liu T; Huang D; Hao L; Xie Y; Shao J
FEBS Lett; 2015 Apr; 589(9):1018-25. PubMed ID: 25771860
[TBL] [Abstract][Full Text] [Related]
72. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
73. Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.
Wang SQ; Liu ST; Zhao BX; Yang FH; Wang YT; Liang QY; Sun YB; Liu Y; Song ZH; Cai Y; Li GF
Oncotarget; 2015 Sep; 6(28):26142-60. PubMed ID: 26317651
[TBL] [Abstract][Full Text] [Related]
74. In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines.
Gaikwad A; Wolf JK; Brown J; Ramondetta LM; Smith JA
J Oncol Pharm Pract; 2009 Mar; 15(1):35-44. PubMed ID: 18753181
[TBL] [Abstract][Full Text] [Related]
75. SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer.
Zheng Z; Li X; Yang B; Xu Q; Zhu X; Hu L; Teng Y
Funct Integr Genomics; 2023 May; 23(2):147. PubMed ID: 37145301
[TBL] [Abstract][Full Text] [Related]
76. [Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma].
Goto T; Yoshimura K; Matsui Y; Shimizu Y; Inoue T; Okubo K; Kamba T; Nishiyama H; Ogawa O
Hinyokika Kiyo; 2011 Dec; 57(12):671-6. PubMed ID: 22240299
[TBL] [Abstract][Full Text] [Related]
77. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
78. Cross-resistance and combined cytotoxic effects of paclitaxel and cisplatin in bladder cancer cells.
Pu YS; Chen J; Huang CY; Guan JY; Lu SH; Hour TC
J Urol; 2001 Jun; 165(6 Pt 1):2082-5. PubMed ID: 11371932
[TBL] [Abstract][Full Text] [Related]
79. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
Schlütermann D; Skowron MA; Berleth N; Böhler P; Deitersen J; Stuhldreier F; Wallot-Hieke N; Wu W; Peter C; Hoffmann MJ; Niegisch G; Stork B
Urol Oncol; 2018 Apr; 36(4):160.e1-160.e13. PubMed ID: 29276062
[TBL] [Abstract][Full Text] [Related]
80. ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer.
Jiang YK; Shuai YJ; Ding HM; Zhang H; Huang C; Wang L; Sun JY; Wei WJ; Xiao XY; Jiang GS
Curr Med Sci; 2023 Jun; 43(3):560-571. PubMed ID: 37142816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]